Clinical Trials Logo

Clinical Trial Summary

Fecal microbiota transplantation (FMT) for the treatment of recurrent Clostridium difficile infection (RCDI) has traditionally been offered as fecal slurry administered by enema, nasogastric tube or endoscopy. Frozen oral capsules have also shown efficacy. The potential advantage of lyophilized FMT is the relative ease of manufacturing and storage compared with fecal slurry.

Sterile fecal filtrate has previously been shown to prevent Clostridium difficile infection (CDI) recurrence, suggesting that live bacteria may not be needed. This study will compare lyophilized sterile fecal filtrate (LSFF) with lyophilized FMT (LFMT) in the treatment of recurrent Clostridium difficile infection (RCDI).


Clinical Trial Description

This prospective double blind randomized pilot study will enroll 40 subjects with recurrent Clostridium difficile infection in a 1:1 ratio to receive either LSFF or LFMT by capsules.

Subjects will receive 15 capsules at week 0 and be assessed at Weeks 1, 4, 12 and 24. If treatment fails, subjects will be given open label LFMT from the same donor. If treatment fails again, another FMT will be offered and the form and route of FMT delivery will be at the discretion of the treating physician. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03353506
Study type Interventional
Source University of Alberta
Contact
Status Completed
Phase Phase 2
Start date February 14, 2018
Completion date October 10, 2019

See also
  Status Clinical Trial Phase
Completed NCT05201079 - Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin Phase 3
Terminated NCT01226992 - Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin Phase 2/Phase 3
Not yet recruiting NCT04960306 - Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection Phase 3
Completed NCT03462459 - Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Recruiting NCT05826418 - Dietary Optimization of Microbiome Recovery Following Fecal Microbiota Transplantation N/A
Completed NCT03497806 - Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection Phase 2
Suspended NCT01202630 - BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection Phase 3
Terminated NCT03973697 - Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection Phase 2
Completed NCT01925417 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea Phase 2
Available NCT03786900 - Fecal Microbiota Transplantation (FMT): PRIM-DJ2727